Identification

Name
RH-1
Accession Number
DB04090  (EXPT02778, DB12103)
Type
Small Molecule
Groups
Experimental, Investigational
Description

RH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma.

Structure
Thumb
Synonyms
Not Available
External IDs
NSC-697726 / RH 1 / RH-1
Categories
Not Available
UNII
IJ5CEP760Y
CAS number
221635-42-3
Weight
Average: 234.2512
Monoisotopic: 234.100442324
Chemical Formula
C12H14N2O3
InChI Key
JKDLOGLNPDVUCX-UHFFFAOYSA-N
InChI
InChI=1S/C12H14N2O3/c1-7-9(13-2-3-13)12(17)8(6-15)10(11(7)16)14-4-5-14/h15H,2-6H2,1H3
IUPAC Name
2,5-bis(aziridin-1-yl)-3-(hydroxymethyl)-6-methylcyclohexa-2,5-diene-1,4-dione
SMILES
CC1=C(N2CC2)C(=O)C(CO)=C(N2CC2)C1=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UNAD(P)H dehydrogenase [quinone] 1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
394347
PubChem Substance
46504603
ChemSpider
349539
ChEMBL
CHEMBL1235676
HET
RH1
PDB Entries
1h66

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedTreatmentAdvanced Solid Tumors / Non-Hodgkin's Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility44.2 mg/mLALOGPS
logP0.22ALOGPS
logP-0.49ChemAxon
logS-0.72ALOGPS
pKa (Strongest Acidic)14.87ChemAxon
pKa (Strongest Basic)-0.56ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.39 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity64.97 m3·mol-1ChemAxon
Polarizability23.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier-0.6136
Caco-2 permeable-0.5275
P-glycoprotein substrateSubstrate0.5517
P-glycoprotein inhibitor INon-inhibitor0.5865
P-glycoprotein inhibitor IIInhibitor0.5726
Renal organic cation transporterNon-inhibitor0.7658
CYP450 2C9 substrateNon-substrate0.74
CYP450 2D6 substrateNon-substrate0.803
CYP450 3A4 substrateNon-substrate0.6656
CYP450 1A2 substrateNon-inhibitor0.6781
CYP450 2C9 inhibitorNon-inhibitor0.7866
CYP450 2D6 inhibitorNon-inhibitor0.8647
CYP450 2C19 inhibitorNon-inhibitor0.7733
CYP450 3A4 inhibitorNon-inhibitor0.8756
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9024
Ames testAMES toxic0.596
CarcinogenicityNon-carcinogens0.8815
BiodegradationNot ready biodegradable0.7613
Rat acute toxicity2.5956 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.601
hERG inhibition (predictor II)Non-inhibitor0.8841
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as p-benzoquinones. These are benzoquinones where the two C=O groups are attached at the 1- and 4-positions, respectively.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
P-benzoquinones
Alternative Parents
Vinylogous amides / N-vinylaziridines / Trialkylamines / Enamines / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
P-benzoquinone / Vinylogous amide / Vinylaziridine / N-vinylaziridine / Tertiary amine / Tertiary aliphatic amine / Organoheterocyclic compound / Enamine / Aziridine / Azacycle
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Superoxide dismutase activity
Specific Function
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vit...
Gene Name
NQO1
Uniprot ID
P15559
Uniprot Name
NAD(P)H dehydrogenase [quinone] 1
Molecular Weight
30867.405 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 15:23